A Novel Small Molecule Supports the Survival of Cultured
Dopamine Neurons and May Restore the Dopaminergic Innervation of the
Brain in the MPTP Mouse Model of Parkinson’s Disease
posted on 2019-09-11, 15:33authored byOleg V. Ardashov, Alla V. Pavlova, Arun Kumar Mahato, Yulia Sidorova, Ekaterina A. Morozova, Dina V. Korchagina, Georgi E. Salnikov, Alexander M. Genaev, Oksana S. Patrusheva, Nikolay S. Li-Zhulanov, Tat’yana
G. Tolstikova, Konstantin P. Volcho, Nariman F. Salakhutdinov
We previously showed
that monoterpenoid (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol 1 alleviates motor manifestations of Parkinson’s disease
in animal models. In the present study, we designed and synthesized
monoepoxides of (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol 1 and evaluated their biological activity in the MPTP mouse
model of Parkinson’s disease. We also assessed the ability
of these compounds to penetrate the blood–brain barrier (BBB).
According to these data, we chose epoxide 4, which potently
restored the locomotor activity in MPTP-treated mice and efficiently
penetrated the BBB, to further explore its potential mechanism of
action. Epoxide 4 was found to robustly promote the survival
of cultured dopamine neurons, protect dopamine neurons against toxin-induced
degeneration, and trigger the mitogen-activated protein kinase (MAPK)
signaling cascade in cells of neuronal origin. Meanwhile, neither
the survival-promoting effect nor MAPK activation was observed in
non-neuronal cells treated with epoxide 4. In the MPTP
mouse model of Parkinson’s disease, compound 4 increased the density of dopamine neuron fibers in the striatum,
which can highlight its potential to stimulate striatal reinnervation
and thus halt disease progression. Taken together, these data indicate
that epoxide 4 can be a promising compound for further
development, not only as a symptomatic but also as a neuroprotective
and neurorestorative drug for Parkinson’s disease.